Clinical Trial Update: Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update describing a short-course combination of trastuzumab and pertuzumab with taxanes for early HER2-positive breast cancer; currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• PACLITAXEL (PACLITAXEL)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING